Clinical Trials Logo

Filter by:
NCT ID: NCT03566238 Completed - PFIC2 Clinical Trials

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

PEDFIC 1
Start date: May 16, 2018
Phase: Phase 3
Study type: Interventional

Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.

NCT ID: NCT03566082 Completed - Clinical trials for Degenerative Joint Disease of Hip

Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - Europe

R3 EU PAS
Start date: May 28, 2009
Phase:
Study type: Observational

The purpose of this prospective, multicenter, single arm study is to confirm the long-term safety and effectiveness of the R3 delta Ceramic Acetabular System PMA (P150030) by evaluating long-term (10 years after surgery) follow-up results.

NCT ID: NCT03565900 Completed - Clinical trials for Pneumococcal Infections

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Start date: September 12, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to 1) evaluate the safety and tolerability, and immunogenicity of blinded V114 and Prevnar 13™ within each vaccination group, and 2) evaluate the safety and tolerability, and immunogenicity of PNEUMOVAX™23 (administered as open label, 12 months after allogeneic hematopoietic stem cell transplant [allo-HSCT] in participants who do not develop chronic graft-versus-host disease [GVHD]).

NCT ID: NCT03564509 Completed - Clinical trials for Controlled Ovarian Stimulation

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

RAINBOW
Start date: May 14, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this phase 2 dose-ranging trial is to investigate the effects of FE 999302 on parameters influencing pregnancy rates in women undergoing Controlled Ovarian Stimulation (COS) with follitropin delta in a long gonadotropin releasing hormone (GnRH) agonist protocol. Furthermore, the study intends: - To investigate the safety of FE 999302 in women undergoing COS with follitropin delta in a long GnRH agonist protocol. - To investigate the potential immunogenicity of FE 999302 in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol. - To estimate the impact of body weight on FE 999302 exposure in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol.

NCT ID: NCT03563014 Completed - Clinical trials for Prostatic Neoplasms, Castration-Resistant

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

BELFIGO
Start date: July 31, 2018
Phase:
Study type: Observational

The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.

NCT ID: NCT03561636 Completed - Health Literacy Clinical Trials

Health Literacy in the General Population in Belgium

Start date: June 1, 2017
Phase:
Study type: Observational

The aims of the study are: - To measure health literacy (HL) levels in a sample composed of members of a health mutual (Solidaris), and its potential associations with several determinants (health, health services consumption, health behaviours...) - To identify potential groups at risk of a lower HL - To identify the determinants of HL level

NCT ID: NCT03560440 Completed - Clinical trials for Gram-Positive Bacterial Infections

Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients

Start date: June 2014
Phase:
Study type: Observational

In this retrospective registry the investigators wish to verify whether the current dosing regime of vancomycin is leading to the appropriate pharmacokinetic targets in pediatric patients. Therefore data will be collected from all pediatric patients hospitalized in University Hospitals Leuven between January 2012 and April 2014 who were treated with vancomycine.

NCT ID: NCT03559621 Completed - Clinical trials for Type 2 Diabetes Mellitus

Mobile-based Lifestyle Intervention in Women With Glucose Intolerance After Gestational Diabetes

MELINDA
Start date: April 14, 2019
Phase: N/A
Study type: Interventional

Although lifestyle modification programs have been shown to be effective in preventing diabetes in older populations, interventions in women with recent gestational diabetes (GDM) clearly need to be adapted to address their unique barriers to behavior change in order to optimize adherence. The low participating rates in many studies using individual or group sessions, reflect how difficult it is to engage women in the first years postpartum. Since women with glucose intolerance (prediabetes) have the highest risk to develop type 2 diabetes (T2DM), we designed the MELINDA pilot study, a randomized controlled trial with 1 year of follow-up to evaluate the efficacy and feasibility of a telephone -and mobile (app) based lifestyle coaching intervention in women with glucose intolerance after a recent history of GDM to promote a healthy lifestyle.

NCT ID: NCT03559257 Completed - Migraine Clinical Trials

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

CONQUER
Start date: July 31, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.

NCT ID: NCT03559062 Completed - Cystic Fibrosis Clinical Trials

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Start date: May 17, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 through 11 years, who are homozygous for the F508del mutation (F/F) or heterozygous for F508del with an eligible residual function mutation (F/RF).